Key result
Nesiritide use was not independently associated with mortality overall, but among CHF patients who developed acute renal failure, it independently predicted mortality (OR 3.73; 95% CI 1.45-9.56).
Why the study?
Does nesiritide increase 60-day mortality in elderly patients with congestive heart failure?
Population
1407 consecutive elderly patients with congestive heart failure (CHF)
Comparison
Nesiritide vs No nesiritide
Design
Cohort
Follow-up
60 days
Authors
Loading...
Caution advised with nesiritide in CHF patients developing acute renal failure; leaves open overall mortality effect pending randomized confirmation.
Cohort (n=1,407)
Does nesiritide increase 60-day mortality in elderly patients with congestive heart failure?
Absolute Event Rate: 10% vs 6%
p-value: p=0.011
While nesiritide is not independently associated with increased mortality in CHF overall, its use in patients who develop acute renal failure significantly increases mortality risk.
Iglesias et al. (2007) conducted a cohort in Congestive heart failure (n=1,407). Nesiritide vs. No nesiritide was evaluated on 60-day mortality (p=0.011). Nesiritide use was not independently associated with mortality overall, but among CHF patients who developed acute renal failure, it independently predicted mortality (OR 3.73; 95% CI 1.45-9.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: